Navigation Links
Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.
Date:11/7/2011

LIBERTY, Mo. and DANBURY, Conn., Nov. 7, 2011 /PRNewswire/ -- Planet Biopharmaceuticals, Inc. and its wholly owned Subsidiaries (collectively, "Planet"), a privately held specialty pharmaceutical company focused on providing products for allergy and asthma sufferers, today announced that it had completed an asset sale of ALLERGY CONTROL PRODUCTS, INC., a Delaware corporation("ACP") to RH ALLERGY ACQUISITION LLC, a New Jersey limited liability company.

Theron E. Odlaug, Ph. D., CEO and Executive Chairman of Planet, commented, "The sale of this business is in line with our strategy to focus on our allergenic extract business through our wholly owned subsidiaries Antigen Laboratories, Inc. and ALO, Inc.  We plan to merge these two remaining Planet subsidiaries at year-end".

Jeffrey Tauber, Managing Member of RH Allergy Acquisition noted "We are excited about this acquisition as it is a logical extension of our allergy prevention and environmental control business. We look forward to a smooth transition and will continue to maintain ACP's offices in Danbury, Connecticut."

For more information about Antigen Laboratories, Inc, please visit http://www.antigenlab.com/


'/>"/>
SOURCE Planet Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. IMPLANET Raises Additional EUR 8 Million (USD 11 Million) to Fuel Deployment
2. WellSpring Pharmaceutical, American Gastroenterological Association, and Steven Bramson of Humanscale Partner With MediaPlanet to Publish One of the Largest Digestive Wellness Campaigns in U.S. History to Overcome Upset Stomach, Nausea, IBS, and Deb
3. Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
4. Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna
5. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
6. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
11. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):